Appraisal consultation document; Ozanimod for treating relapsing–remitting multiple s

In DRAFT guidance, NICE does not recommend ozanimod for treating relapsing-remitting multiple sclerosis in adults with clinical or imaging features of active disease. Ozanimod’s effect on the progression of disability in unclear and cost-effectiveness estimates are uncertain.

National Institute for Health and Care Excellence